Table 1.
Baseline characteristics before and after matching.
Unmatched |
Matched |
|||||
---|---|---|---|---|---|---|
Control n = 3973 | Case n = 70 | P value | Control n = 195 | Case n = 65 | P value | |
Ages (years) | 31.0 (29.0, 35.0) | 32.0 (29.8, 36.0) | 0.374 | 32.0 (29.0, 35.0) | 31.0 (29.0, 34.0) | 0.718 |
BMI (kg/m2) | 21.9 (21.1, 22.4) | 21.2 (19.4, 23.2) | 0.034 | 21.9 (20.8, 22.4) | 20.6 (19.1, 23.3) | 0.064 |
ART times | 1 (1, 1) | 1 (1, 2) | 0.021 | 1 (1, 2) | 1 (1, 2) | 0.477 |
Infertility durations (years) | 3 (1, 4) | 3 (1, 4) | 0.955 | 3 (1, 4) | 3 (1, 4) | 0.845 |
Infertility types | 0.844 | 0.255 | ||||
Primary (%) | 66.0 (2623) | 67.1 (47) | 64.6 (126) | 72.3 (47) | ||
Secondary (%) | 34.0 (1350) | 32.9 (23) | 35.4 (69) | 27.7 (18) | ||
Infertility causes | 0.340 | 0.731 | ||||
Female factor (%) | 60.1 (2388) | 57.1 (40) | 53.8 (105) | 53.8 (35) | ||
male factor (%) | 13.1 (520) | 8.6 (6) | 6.2 (12) | 9.2 (6) | ||
both female and male factors (%) | 21.5 (853) | 30.0 (21) | 36.9 (72) | 32.3 (21) | ||
unexplained (%) | 5.3 (212) | 4.3 (3) | 3.1 (6) | 4.6 (3) | ||
COS protocols | 0.637 | 0.447 | ||||
GnRH agonist protocol (%) | 37.0 (1469) | 34.3 (24) | 37.9 (74) | 36.9 (24) | ||
GnRH antagonist protocol (%) | 52.2 (2074) | 51.4 (36) | 47.2 (92) | 53.8 (35) | ||
Other protocola (%) | 10.8 (430) | 14.3 (10) | 14.9 (29) | 9.2 (6) | ||
Operation types | 0.159 | 0.830 | ||||
IVF (%) | 61.7 (2450) | 54.3 (38) | 54.4 (106) | 53.8 (35) | ||
ICSI (%) | 34.0 (1353) | 44.3 (31) | 42.1 (82) | 44.6 (29) | ||
R-ICSI (%) | 4.3 (170) | 1.4 (1) | 3.6 (7) | 1.5 (1) |
Note: BMI, body mass index; ART, assisted reproductive technique; COS, controlled ovarian stimulation; GnRH, gonadotrophin releasing hormone; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; R-ICSI, rescue intracytoplasmic sperm injection;
Continuous variables were presented as the median (first quartile, third quartile).
Categorical variables were presented as% (n).
P < 0.05 was considered statistically significant.
aOther protocol: including mild stimulation and luteal phase stimulation protocols.